# Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Canonical URL: https://biopharmsignal.com/news/EDIT/editas-medicine-announces-edit-401-poster-presentation-at-the-american-heart-ass-ac9f8eb6
Ticker: EDIT
Company: Editas Medicine
Source: Editas Medicine
Published: 2025-11-03 14:00 EST
## Summary

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing...

## Article Body
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.

American Heart Association (AHA) Scientific Sessions 2025 Title: A transformative LDL cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates Session Date and Time: Saturday, November 8, 10:45 a.m. – 11:45 a.m. CT Session Title: Cutting-Edge Gene and Precision Therapies Presentation Room: Basic Science Zone Presenter: Anshul Gupta, Vice President, Preclinical Development at Editas Medicine Final Abstract Number: 4364195

The accepted abstract is available on the AHA website . A copy of the poster presentation will be made available on the “ Posters & Presentations ” section of the Company’s website at the time of the presentation and will remain accessible following the event.

About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
## Recent Company News
- 2026-05-28 20:01 EST — [Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-confer-ef3968d7) — Source: Editas Medicine
- 2026-05-26 13:05 EST — [Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-pricing-of-up-to-319-4-million-public-offering-127eec22) — Source: Editas Medicine
- 2026-05-26 10:15 EST — [Editas Medicine Announces Proposed Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-proposed-public-offering-1685aa73) — Source: Editas Medicine
- 2026-05-26 10:01 EST — [Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress](https://biopharmsignal.com/news/EDIT/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductio-8f1aef48) — Source: Editas Medicine
- 2026-05-14 10:01 EST — [Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401--a6308965) — Source: Editas Medicine
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)